linjc16/ctgov huggingface dataset:
Study the Effect of Water Kefir Consumption on the Gut Microbiome in Healthy Adults

Study Overview
=================
Brief Summary
-----------------
The goal of this intervention study is to analyse the microbiota composition after the water kefir consumption. The main questions are to evaluate the potential probiotic drink can have beneficial effect on the gut microbiota. Participants will consume the water kefir for two weeks and microbiota will be analysed. Researchers will compare the microbiota composition before and after consumption.

Official Title
-----------------
Analysis of the Intestinal Flora Composition After Consumption of Water Kefir

Conditions
-----------------
Healthy Diet, Gastrointestinal Microbiome, Probiotics

Intervention / Treatment
-----------------
* Dietary Supplement: Water Kefir beverage


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: 18-65 years of age. must be able to complete the form digitally. Exclusion Criteria: must not be diagnosed with gastrointestinal diseases, autoimmune diseases or have diseases or medications that cause immune deficiency such as MS, type 1 diabetes, cancer or HIV. must not take antibiotics during the study period.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Active group<br> | Dietary Supplement: Water Kefir beverage<br>* Participants will consume the water kefir beverage for two weeks.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| 16S metagenomics based measurement of the bacterial diversity (alpha- and beta diversity indices), and the composition (relative abundance of the bacterial taxa in each sample) | Potential changes of microbiome after consumption of the water kefir will be assessed by analyzing the 16S metagenomics | up to 24 weeks |
Exhaled Breath Condensate in Allogeneic Stem Cell Recipients and the Value in Follow-up

Study Overview
=================
Brief Summary
-----------------
The most effective treatment of hematologic malignancies and some benign hematological diseases is allogeneic stem cell transplantation therapy. Pulmonary complications can occur after allogeneic stem cell transplantation. And these complications effect mortality and morbidity in these patients. In this study we want to investigate the use of exhaled breath condensate (EBC) collection which is a simple and completely noninvasive method. By this way we hope to detect pulmonary complications early. EBC, has been implicated in the pathophysiology of inflammatory airway diseases such as cystic fibrosis, asthma, chronic obstructive pulmonary disease (COPD) and bronchiectasis. EBC, has not been investigated before in patients who underwent stem cell transplantation.

Official Title
-----------------
Exhaled Breath Condensate in Allogeneic Stem Cell Recipients and Value in Follow-up

Conditions
-----------------
Exhaled Breath Condensate

Intervention / Treatment
-----------------
* Other: Exhaled breath condensate


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: hematologic malignancies or benign hematological diseases that allogeneic stem cell transplantation performed Exclusion Criteria: allogeneic stem cell transplantation patients with Asthma or COPD

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 75 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| EBC level<br>Exhaled breath condensate level of allogeneic stem cell transplantation patients | Other: Exhaled breath condensate<br>* Breath condensate samples will be collected with a commercially available condenser (EcoScreen®, Erich Jaeger, Germany). Subjects will breathe through a mouthpiece and a two-way non-rebreathing value in which inspiratory and expiratory air were separated, and saliva was trapped. They will be asked to breathe at a normal frequency and tidal volume for 15 minutes while wearing nose clips, allowing collection of 1.5-2.5 mL of condensate. After collecting this, pH will be measured and the waste collection will be stored at -80 degrees. Then 8 isoprostane and nitrotyrosine will be measured collectively<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The pH level of exhaled breath condansate |  | 2 years | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The nitrotyrosine and 8-isoprostane levels of exhaled breath condansate |  | 2 years | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Exhaled breath condensate, allogeneic stem cell transplantation, pulmonary complications
Phase 2 Study to Evaluation the Safety and Efficacy of Orally Administered KL7016 in Patients With Dry Eye Syndrome

Study Overview
=================
Brief Summary
-----------------
This is a controlled study to determine the effectiveness and safety of KL7016 in the treatment of adult patients with dry eye syndrome (DES).

Official Title
-----------------
A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group, 12 Weeks, Phase II Clinical Study to Evaluate the Safety and Efficacy of Orally Administered KL7016 in Patients With Dry Eye Syndrome

Conditions
-----------------
Dry Eye Syndrome

Intervention / Treatment
-----------------
* Drug: KL7016 900mg
* Drug: KL7016 600mg
* Drug: Placebo


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Corneal staining score of ≥5 in either eye by the National Eye Institute/Industry Workshop guidelines Schirmer test score (without anesthesia) < 7 mm/5 min in either eye Willing to use no topical ocular treatments, other than REFRESH TEARS® for the duration of the trial Exclusion Criteria: Intraocular surgery within 3months Persistent intraocular inflammation or infection Corneal transplantation or neurotrophic keratitis Stevens-Johnson Syndrome Ocular herpes simplex virus infection Concomitant use of contact lenses or use within 3months Silicone lacrimal punctal occlusion or cauterization of the punctum within 3months Vision correction surgery without DES within 12months Unstable use of methotrexate or Disease-modifying drugs

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: KL7016 900mg<br> | Drug: KL7016 900mg<br>* oral administration, 150mg 3tab, bid<br>|
| Placebo Comparator: Placebo<br> | Drug: Placebo<br>* oral administration, 150mg 3tab, bid<br>|
| Experimental: KL7016 600mg<br> | Drug: KL7016 600mg<br>* oral administration, 150mg 3tab, bid<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change in corneal staining score |  | baseline, 12 weeks | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change in schirmer test score |  | baseline, 4weeks, 8weeks, 12 weeks | 
| Change in OSDI(Ocular Surface Disease Index) |  | baseline, 4weeks, 8weeks, 12 weeks | 
| Change in TFBUT(Tear Film Break-up Time) |  | baseline, 4weeks, 8weeks, 12 weeks | 
| Change in conjunctival staining score |  | baseline, 4weeks, 8weeks, 12 weeks | 
| Change in corneal staining score |  | baseline, 4weeks, 8weeks |
Collagenase in the Treatment of Zone II Flexor Tendon Adhesions in the Hand

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to dissolve flexor tendon adhesions associated with failed tendon repair surgery.

Detailed Description
-----------------
In an open label study, collagenase injection therapy was investigated in 3 subjects for it's ability to lyse flexor tendon adhesions in zone II of the hand. Results indicate that two of three subjects had improved range of finger motion at the PIP and DIP joints. This may obviate the need for patients to have tenolysis hand surgery to correct the finger flexion contracture of the PIP and DIP joints. Detailed controlled studies remain to be done.

Official Title
-----------------
Study of Collagenase Injection Therapy for Treatment of Zone II Flexor Tendon Adhesions in the Hand

Conditions
-----------------
Adhesion of Flexor Tendon of Hand

Intervention / Treatment
-----------------
* Drug: Collagenase
* Drug: Collagenase injection


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: zone II flexor tendon adhesion of at least one finger Exclusion Criteria: any chronic, serious or uncontrolled medical condition inability to conform to study visits (12-15 per year)

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 75 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Collagenase Injection<br>Injection of collagenase into adhesion restricting tendon gliding | Drug: Collagenase<br>* Collagenase injection into adhesion restricting tendon gliding<br>* Other names: Collagenase Clostridium Histolyticum;Drug: Collagenase injection<br>* injection of collagenase into adhesion restricting tendon gliding<br>* Other names: Collagenase Clostridium Histolyticum;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Restoration of PIP and DIP joint motion. |  | 6 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Hand Grip strength (kg) |  | 6 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Flexor Tendon Adhesions, Zone II of the Hand
Renal Perfusion, Filtration and Oxygenation During Cardiopulmonary Bypass (CPB)

Study Overview
=================
Brief Summary
-----------------
Acute kidney injury is a common complication after cardiac surgery with cardiopulmonary bypass (CPB). This study aims to investigate the effects of CPB on renal perfusion, filtration and oxygenation.

Detailed Description
-----------------
After approval of the regional ethics committee, patients (n=16) undergoing combined cardiac surgery procedures during normothermic CPB will be included after informed consent. Systemic and renal variables will be measured by pulmonary artery and renal vein catheters. Glomerular filtration rate (GFR) will be measured by renal extraction of 51Cr-EDTA and renal blood flow (RBF) by the infusion clearance technique for para-aminohippuric acid (PAH) corrected for by renal extraction of PAH. Repeated measures ANOVA followed by Fisher's PLSD post-hoc test were used for statistical analyses

Official Title
-----------------
Renal Perfusion, Filtration and Oxygenation During Cardiopulmonary Bypass (CPB)

Conditions
-----------------
Complication of Extracorporeal Circulation, Renal Impairment

Intervention / Treatment
-----------------
* Procedure: cardiopulmonary bypass


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Preserved left ventricular function (LVEF > 50%) Normal preoperative S-creatinine Exclusion Criteria: Contraindications to radiocontrast Cardiac transplantation och dissection

Ages Eligible for Study
-----------------
Minimum Age: 19 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Procedure: cardiopulmonary bypass|During cardiac surgery, the subjects are routinely undergoing cardiopulmonary bypass|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Renal Blood Flow (RBF) | Renal blood flow measured with PAH clearance | 6 hours | 
| Glomerular Filtration Rate (GFR) | GFR measured by renal extraction of 51Cr-EDTA | 6 hours | 
| Renal Oxygenation | Renal oxygen extraction, defined as renal oxygen consumption divided by renal oxygen delivery | 6 hours | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Excretion of NAG | Urinary biomarker of tubular renal injury | 24 hours | 
| Development of Acute Kidney Injury (AKI) | AKI according to AKIN criteria | 72 hours |
Imaging-based Deep Learning for Lung Cancer Diagnosis and Staging

Study Overview
=================
Brief Summary
-----------------
Lung cancer diagnosis and staging are two fundamental and critical issue in clinical lung cancer management and therapeutic decision-making. Invasive procedures for pathologic analysis are gold standard for diagnosis and staging, however, invasive procedures related-complications are inevitable. Noninvasive medical imaging is a powerful tool, however there is almost no room for improvement just according to the experience of radiologist and clinician. The researchers will investigate the role of computer based deep learning of medical imaging in the diagnosis of lesion of lung, lymph node and other sites suspected with metastasis.

Detailed Description
-----------------
Radiologist

Official Title
-----------------
The Role of CNN Architecture-based Transfer Learning of Medical Imaging in Lung Cancer Diagnosis and Staging

Conditions
-----------------
Lung Cancer

Intervention / Treatment
-----------------
* Procedure: surgery
* Procedure: punture


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Pathological diagnosis of lung cancer PET/CT or CT examination before any cancer-specific treatment Exclusion Criteria: A history of other malignancies

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 75 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| cancer cell involvement predicted by deep learning<br>the participants with lesions of lung, lymph node or other sites predicted as positive for cancer cell involvement by imaging based deep learning. | Procedure: surgery<br>* treatment intent surgery<br>Procedure: punture<br>* diagnostic punture<br>|
| no cancer cell involvement predicted by deep learning<br>the participants with lesions of lung, lymph node or other sites predicted as negative for cancer cell involvement by imaging based deep learning. | Procedure: surgery<br>* treatment intent surgery<br>Procedure: punture<br>* diagnostic punture<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| pathologic result revealed cancer cell involvement in lesion |  | 1 month after the pathologic test |
Study to Determine the Utility of Wound Vacuum Assisted Closure (VAC) Compared to Conventional Saline Dressing Changes

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to look at the use of the wound vacuum assisted closure (VAC) versus standard wet to dry dressing in treating lower leg fasciotomies.

Official Title
-----------------
A Prospective Study to Determine the Utility of Vacuum Assisted Closure (VAC) Compared to Conventional Saline Dressing Changes With Regards to Lower Extremity Fasciotomy Wound Healing, Complications, Cost and Patient and Nursing Satisfaction

Conditions
-----------------
Wounds, Compartment Syndromes

Intervention / Treatment
-----------------
* Device: Wound Care -Wound Vacuum Assisted Closure (VAC)
* Procedure: Wound Care - Wet to Dry Dressing Changes


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: four compartment fasciotomies performed on one or both lower extremities subject and/or subject's legally authorized representative (next-of-kin) has voluntarily signed and dated informed consent. Exclusion Criteria: inability to place wound VAC contraindications for wound VAC use pregnant females prisoners

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 99 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Intervention/Treatment |
| --- |
|Device: Wound Care -Wound Vacuum Assisted Closure (VAC)|nan|
|Procedure: Wound Care - Wet to Dry Dressing Changes|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Rate of wound healing |  |  | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Time to delayed primary wound closure |  |  | 
| Time to completion of secondary healing |  |  | 
| Patient satisfaction |  |  | 
| Nurse satisfaction |  |  | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
wounds-open
Mortality Predictions With Scorring Indices in Gastrointestinal Tumours

Study Overview
=================
Brief Summary
-----------------
The ASA-PS, SORT and Sarcopenia scores of the patients who will undergo surgery for a gastrointestinal tumor will be recorded. Thus, the correlation between preoperative indices and mortality/morbidity will be evaluated.

Detailed Description
-----------------
ASA-PS values of patients who are planned to be operated due to gastrointestinal tumor will be recorded, then SORT (The Surgical Outcome Risk Tool) values will be calculated from sortsurgery.com. Sarcopenia measurements will be made by the radiologist from the abdomen CT at the L-3 level. The pathology results of the patients will be recorded. Morbidity and mortality rates will be recorded in the short and long term.

Official Title
-----------------
The Effectiveness of ASA, SORT and Sarcopenia Indices in Estimating Mortality and Morbidity in Gastrointestinal Tumour Surgery

Conditions
-----------------
Gastrointestinal Tumours

Intervention / Treatment
-----------------
* Other: ASA-PS
* Other: SORT
* Other: Sarcopenia


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: >18 years of age operation for gastrointestinal tumors Exclusion Criteria: patient rejection

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Other: ASA-PS|The American Society of Anesthesiologists classification of physical status (ASA PS) is a scale consisting of 6 classes showing the preoperative comorbidity of the patient.|
|Other: SORT|Surgical outcome risk tool (SORT) is a scale used to estimate patient preoperative mortality/ morbidity, measured from sortsurgery.com.|
|Other: Sarcopenia|Sarcopenia represents a loss of muscle strength and mass in older individuals and people who have tumors. Sarcopenia score is valuable in predicting preoperative mortality/ morbidity|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| rate of mortality | death depending on the operation | 6 months after surgery | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
ASA-PS, SORT, Sarcopenia, Mortality, Morbidity
Intrathecal Fentanyle Versus Dexamethasone in Gynacological Laparoscopic Surgeries

Study Overview
=================
Brief Summary
-----------------
Laparoscopy was first introduced to the medical field of in the middle of the last century. It revolutionized the surgical interventions; it reduced the total medical expenditures and hastened postoperative recovery . General anaesthesia (GA) was considered the only anesthetic technique suitable for laparoscopic interventions, and several myths and facts prevented regional anaesthesia (RA) implementation. Respiratory and Cardiovascular impairment were the main aspects of concern which are thought to be best controlled by GA

Official Title
-----------------
Intrathecal Fentanyle Versus Dexamethasone in Patients Under Going Gynacological Laparoscopic Surgeries

Conditions
-----------------
Intraoperativ Pain

Intervention / Treatment
-----------------
* Drug: intrathecal fentanyle
* Drug: dexamethasone
* Drug: saline


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: ASA I, II elective gynacological laparoscopic surgery Exclusion Criteria: patient refusal chronic kidney and hepatic diseases

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 40 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: fentanyle group<br> | Drug: intrathecal fentanyle<br>* 25 mic fentanyle added to heavy bupivacaine for spinal anesthesia<br>|
| Active Comparator: dexamethasone group<br> | Drug: dexamethasone<br>* 8 mg dexamethasone give intrathecally for spinal anaesthesia<br>|
| Placebo Comparator: control group<br> | Drug: saline<br>* normal saline will be mixed with bupivacaine intrathecally<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| intraoperative pain | pain measured by VAS score =from 0 to 10 0-3 is mild pain 3-6 moderate pain 6-10 sever pain | 60 minutes |